NuCana (NCNA) vs Xenetic Biosciences (XBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Xenetic Biosciences is the larger company by market cap ($5.0 million vs $4.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | NCNA | XBIO |
|---|---|---|
| Share price | $1.12 | $2.15 |
| Market cap | $4.66M | $5.04M |
| 1-day change | -1.75% | -2.71% |
| EPS (TTM) | $0.00 | $-1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.40 | $10.24 |
| 52-week low | $0.948 | $1.87 |
| Distance from 52-week high | -82.50% | -79.00% |
| Average volume | 123.99K | 87.71K |
| Shares outstanding | 4.16M | 2.34M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
NCNA vs XBIO FAQ
Which is bigger, NuCana or Xenetic Biosciences?
Xenetic Biosciences (XBIO) is larger, with a market capitalization of $5.04M compared with $4.66M for NuCana (NCNA).
Are NuCana and Xenetic Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.